The US Federal Drug Administration (FDA) has issued near-identical warning letters to four biologics companies regarding their at-home blood testing kits, citing concerns over safety and reliability.
The agency alleges that the businesses were providing human immunodeficiency virus (HIV) serological diagnostic dried blood spot (DBS) card self-collection kits (HIV DBS